Soleno Therapeutics, Inc. (SLNO)

Compare

67.43

-4.01

(-5.62%)

As of 2:16:23 PM EDT. Market Open.

High Growth Tech Stocks To Watch In The US April 2025

Over the last 7 days, the United States market has dropped 3.4%, yet it remains up by 6.1% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and resilience amidst fluctuating market conditions.

Simply Wall St. 7 hours ago

VRRM

SLNO
-5.62%
ABBV
Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week?

We recently published a list of 10 Stocks Outperform Broader Market Last Week. In this article, we are going to take a look at where Soleno Therapeutics Inc. (NASDAQ:SLNO) stands against other stocks that outperformed broader market last week. Wall Street’s main indices traded lower week-on-week as investor sentiment continued to be dragged by the […]

Insider Monkey 2 days ago

SLNO
-5.62%
^GSPC
Why Soleno Therapeutics Inc. (SLNO) Went Up On Friday?

We recently published a list of 10 Firms End Friday Strong; 3 Reach All-Time Highs. In this article, we are going to take a look at where Soleno Therapeutics Inc. (NASDAQ:SLNO) stands against other firms that end Friday strong. Wall Street’s main indices finished the trading week in the negative territory as investor sentiment was […]

Insider Monkey 3 days ago

SLNO
-5.62%
^GSPC
Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday?

We recently published a list of 10 Stocks Jump, Defy Market Uncertainties on Thursday. In this article, we are going to take a look at where Soleno Therapeutics Inc. (NASDAQ:SLNO) stands against other stocks that jumped, defying market uncertainties on Thursday. The stock market extended losses on Thursday, with all the major indices ending in […]

Insider Monkey 4 days ago

SLNO
-5.62%
^GSPC
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower

Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech stock rocketed.

Investor's Business Daily 4 days ago

AARD

SLNO
-5.62%
Tiny Drugmaker Soars on FDA Win to Treat Never-Ending Hunger

(Bloomberg) -- Soleno Therapeutics jumped on Thursday after the drugmaker won US approval for its drug to treat insatiable hunger caused by a genetic disorder.Most Read from BloombergWhy Did the Government Declare War on My Adorable Tiny Truck?Gold-Rush Fever Returns to Historic New Zealand Mining TownHow SUVs Are Making Traffic WorseTrump Slashed International Aid. Geneva Is Feeling the Impact.These US Bridges Face High Risk of Catastrophic Ship StrikesShares of the Redwood City, California-bas

Bloomberg 4 days ago

SLNO
-5.62%
Soleno wins FDA approval for Prader-Willi hyperphagia treatment

The drug, named Vykat XR, will be available to patients in the US with Prader-Willi syndrome from April 2025.

Pharmaceutical Technology 4 days ago

SLNO
-5.62%
GLDAF
Soleno stock skyrockets on FDA drug approval

Soleno Therapeutics (SLNO) stock is skyrocketing after the company received FDA approval for its new drug to treat excessive hunger for patients with Prader-Willi syndrome. Wealth host Brad Smith is joined by Yahoo Finance's Julie Hyman to discuss the stock's movement. To watch more expert insights and analysis on the latest market action, check out more Wealth here.

Yahoo Finance Video 5 days ago

SLNO
-5.62%
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug

Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients.

Zacks 5 days ago

SLNO
-5.62%
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome

First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26th, at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYKAT XR (diazoxide choline) extended-release tablets, previou

GlobeNewswire 5 days ago

SLNO
-5.62%
Exploring US High Growth Tech Stocks In March 2025

Over the last 7 days, the United States market has experienced a slight decline of 1.3%, yet it has shown resilience with a 15% increase over the past year and earnings forecast to grow by 14% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to sustain growth amidst fluctuating market conditions.

Simply Wall St. 29 days ago

SLNO
-5.62%
NOW

ASND
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter and full-year ended December 31, 2024. Full Year 2024 and Recent Corporate Highlights Regulatory New Drug Application (NDA) for diazoxide choline extended-release tablets (DCCR) for the treatment of Prader-Will

GlobeNewswire last month

SLNO
-5.62%
Soleno Therapeutics to Participate in Upcoming February Investor Conferences

REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February: Guggenheim SMID Cap Biotech ConferencePresentation Date: Thursday, February 6, 2025 at 2:00 PM ETPresentation Format: Fireside ChatWebcast: https://wsw.com/webcast/guggen2/slno/2028708 Oppen

GlobeNewswire last month

SLNO
-5.62%
High Growth Tech Stocks to Watch in January 2025

Over the last week, the United States market saw a 3.1% increase, contributing to a 24% climb over the past year, with earnings forecasted to grow by 15% annually. In this environment of robust growth, identifying high-growth tech stocks that align with these optimistic projections can be crucial for investors looking to capitalize on emerging opportunities in this dynamic sector.

Simply Wall St. 2 months ago

KRYS

LEGN

SLNO
-5.62%
Is Soleno Therapeutics (SLNO) the Top Small Cap Stock to Buy with the Highest Upside Potential?

We recently published a list of the Top 10 Small Cap Stocks to Buy with the Highest Upside Potential. In this article, we are going to take a look at where Soleno Therapeutics, Inc. (NASDAQ:SLNO) stands against other top small cap stocks to buy with the highest upside potential. What Would 2025 Look Like for […]

Insider Monkey 2 months ago

SLNO
-5.62%
Soleno Therapeutics, Inc. (NASDAQ:SLNO): When Will It Breakeven?

We feel now is a pretty good time to analyse Soleno Therapeutics, Inc.'s ( NASDAQ:SLNO ) business as it appears the...

Simply Wall St. 2 months ago

SLNO
-5.62%
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC

Up to $200 million financing, includes $50 million upfrontREDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it has entered into a loan and security agreement with Oxford Finance LLC and its affiliates (Oxford) for up to $200 million. “This financing significantly strengthens our financial position, providing addition

GlobeNewswire 3 months ago

SLNO
-5.62%
High Growth Tech Stocks to Watch in November 2024

The United States market has shown robust performance recently, with a 2.0% increase over the last week and a substantial 32% climb in the past year, while earnings are projected to grow by 15% annually in the coming years. In this vibrant environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to maintain momentum alongside these promising market trends.

Simply Wall St. 4 months ago

SLNO
-5.62%
VRTX

TENB
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time. A live audio webcast and replay of the fireside chat will be available in the Investors section on the

GlobeNewswire 4 months ago

SLNO
-5.62%
FDA delays decision of Soleno’s Prader-Willi syndrome drug

The new Prescription Drug User Fee Act (PDUFA) date for diazoxide choline extended-release (DCCR) is slated for 27 March 2025.

Pharmaceutical Technology 4 months ago

SLNO
-5.62%
GLDAF

Performance Overview

Return	SLNO	S&P 500 (^GSPC)
YTD	+50.02%	-4.89%
1-Year	+62.53%	+6.68%
3-Year	+2,040.79%	+23.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Soleno Therapeutics, Inc. (SLNO)

High Growth Tech Stocks To Watch In The US April 2025

Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week?

Why Soleno Therapeutics Inc. (SLNO) Went Up On Friday?

Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday?

Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower

Tiny Drugmaker Soars on FDA Win to Treat Never-Ending Hunger

Soleno wins FDA approval for Prader-Willi hyperphagia treatment

Soleno stock skyrockets on FDA drug approval

SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug

Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome

Exploring US High Growth Tech Stocks In March 2025

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Soleno Therapeutics to Participate in Upcoming February Investor Conferences

High Growth Tech Stocks to Watch in January 2025

Is Soleno Therapeutics (SLNO) the Top Small Cap Stock to Buy with the Highest Upside Potential?

Soleno Therapeutics, Inc. (NASDAQ:SLNO): When Will It Breakeven?

Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC

High Growth Tech Stocks to Watch in November 2024

Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

FDA delays decision of Soleno’s Prader-Willi syndrome drug

Performance Overview